Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Ozgur Kan, Coskun Simsir, Cem Somer Atabekoglu & Murat Sonmezer. (2019) The impact of adding hp-hMG in r-FSH started GnRH antagonist cycles on ART outcome. Gynecological Endocrinology 35:10, pages 869-872.
Read now
Read now
Enrico Papaleo, Carlo Alviggi, Giorgio Lorenzo Colombo, Claudio Pisanelli, Claudio Ripellino, Salvatore Longobardi & Pier Luigi Canonico. (2014) Cost-effectiveness analysis on the use of rFSH + rLH for the treatment of anovulation in hypogonadotropic hypogonadal women. Therapeutics and Clinical Risk Management 10, pages 479-484.
Read now
Read now
Francisco Fábregues, Montserrat Creus, Gemma Casals, Francisco Carmona & Juan Balasch. (2013) Outcome from consecutive ICSI cycles in patients treated with recombinant human LH and those supplemented with urinary hCG-based LH activity during controlled ovarian stimulation in the long GnRH-agonist protocol. Gynecological Endocrinology 29:5, pages 430-435.
Read now
Read now
Articles from other publishers (24)
Valerie Strezsak, Arthur Allignol, Klaus Bühler, Robert Fischer, Julie Hubbard, Salvatore Longobardi, Monica Lispi, Joan Schertz & Patrice Verpillat. (2023) Dosing Characteristics of Recombinant Human Luteinizing Hormone or Human Menopausal Gonadotrophin-Derived LH Activity in Patients Undergoing Ovarian Stimulation: A German Fertility Database Study. Gynecologic and Obstetric Investigation 88:4, pages 214-225.
Crossref
Crossref
Anatoliy V. Kaminsky & Oksana O. Chaika. (2022) HORMONAL STATUS OF PATIENTS WITH A PREDICTED WEAK RESPONSE OF THE OVARIES TO GONADOTROPIN STIMULATION. Wiadomości Lekarskie 75:10, pages 2374-2378.
Crossref
Crossref
Ming-Jer Chen, Yu-Chiao Yi, Hwa-Fen Guu, Ya-Fang Chen, Hsiao-Fan Kung, Jui-Chun Chang, Shih-Ting Chuan & Li-Yu Chen. (2022) A retrospective, matched case-control study of recombinant LH versus hMG supplementation on FSH during controlled ovarian hyperstimulation in the GnRH-antagonist protocol. Frontiers in Endocrinology 13.
Crossref
Crossref
Chenyang Huang, Xiaoyue Shen, Jie Mei, Yanxin Sun, Haixiang Sun & Jun Xing. (2022) Effect of recombinant LH supplementation timing on clinical pregnancy outcome in long-acting GnRHa downregulated cycles. BMC Pregnancy and Childbirth 22:1.
Crossref
Crossref
Noemi Di Segni, Andrea Busnelli, Matteo Secchi, Federico Cirillo & Paolo Emanuele Levi-Setti. (2022) Luteinizing hormone supplementation in women with hypogonadotropic hypogonadism seeking fertility care: Insights from a narrative review. Frontiers in Endocrinology 13.
Crossref
Crossref
E.B. Rudakova, O.F. Serova, T.V. Strizhova, E.A. Fedorova & S.Ya. Ostrina. (2022) The Role of Luteinizing Hormone in Ovarian Stimulation of IVF Programs (literature review). Problemy reproduktsii 28:1, pages 129.
Crossref
Crossref
Klaus F. Bühler, Robert Fischer, Patrice Verpillat, Arthur Allignol, Sandra Guedes, Emmanuelle Boutmy, Wilma Bilger, Emilia Richter & Thomas D’Hooghe. (2021) Comparative effectiveness of recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa) versus highly purified urinary human menopausal gonadotropin (hMG HP) in assisted reproductive technology (ART) treatments: a non-interventional study in Germany. Reproductive Biology and Endocrinology 19:1.
Crossref
Crossref
Raoul Orvieto, Christos A. Venetis, Human M. Fatemi, Thomas D’Hooghe, Robert Fischer, Yulia Koloda, Marcos Horton, Michael Grynberg, Salvatore Longobardi, Sandro C. Esteves, Sesh K. Sunkara, Yuan Li & Carlo Alviggi. (2021) Optimising Follicular Development, Pituitary Suppression, Triggering and Luteal Phase Support During Assisted Reproductive Technology: A Delphi Consensus. Frontiers in Endocrinology 12.
Crossref
Crossref
Klaus F. Bühler. (2020) Commentary: Management Strategies for POSEIDON Groups 3 and 4. Frontiers in Endocrinology 10.
Crossref
Crossref
Raoul Orvieto. (2019) HMG versus recombinant FSH plus recombinant LH in ovarian stimulation for IVF: does the source of LH preparation matter?. Reproductive BioMedicine Online 39:6, pages 1001-1006.
Crossref
Crossref
Tanja Panić-Janković & Goran Mitulović. 2019. Embryology - Theory and Practice. Embryology - Theory and Practice.
Tanja Panić‐Janković & Goran Mitulović. (2019) Human chorionic gonadotrophin pharmaceutical formulations of urinary origin display high levels of contaminant proteins–A label‐free quantitation proteomics study. ELECTROPHORESIS 40:11, pages 1622-1629.
Crossref
Crossref
John L. Yovich. 2019. How to Prepare the Egg and Embryo to Maximize IVF Success. How to Prepare the Egg and Embryo to Maximize IVF Success
94
120
.
Ensieh Shahrokh Tehraninejad, Mina Farshbaf Taghinejad, Batool Hossein Rashidi & Fedyeh Haghollahi. (2017) Controlled ovarian stimulation with r-FSH plus r-LH vs. HMG plus r-FSH in patients candidate for IVF/ICSI cycles: An RCT. International Journal of Reproductive BioMedicine 15:7, pages 435-440.
Crossref
Crossref
Baiju Ahemmed, Vani Sundarapandian, Rohit Gutgutia, Sathya Balasubramanyam, Richa Jagtap, Reeta Biliangady, Priti Gupta, Sachin Jadhav, Ruma Satwik, Pavitra Raj Dewda, Priti Thakor & Sandro C. Esteves. (2017) Outcomes and Recommendations of an Indian Expert Panel for Improved Practice in Controlled Ovarian Stimulation for Assisted Reproductive Technology. International Journal of Reproductive Medicine 2017, pages 1-14.
Crossref
Crossref
K. Yu. Bojarskiy & T. A. Libova. (2016) The LH role in ovarian stimulation. Problemy reproduktsii 22:2, pages 17.
Crossref
Crossref
Alberto Revelli, Grazia Pettinau, Gemma Basso, Andrea Carosso, Alessandro Ferrero, Cecilia Dallan, Stefano Canosa, Gianluca Gennarelli, Daniela Guidetti, Claudia Filippini & Chiara Benedetto. (2015) Controlled Ovarian Stimulation with recombinant-FSH plus recombinant-LH vs. human Menopausal Gonadotropin based on the number of retrieved oocytes: results from a routine clinical practice in a real-life population. Reproductive Biology and Endocrinology 13:1.
Crossref
Crossref
K. V. Krasnopol'skaya, T. A. Nazarenko, A. N. Beketova, M. M. Leviashvili, N. Yu. Sharipova & I. Yu. Ershova. (2015) Human derived and recombinant gonadotropins (Pergoveris versus Bravelle+Menopur) in IVF-ICSI cycles. Problemy reproduktsii 21:2, pages 45.
Crossref
Crossref
Sandro C. Esteves & Carlo Alviggi. 2015. Principles and Practice of Controlled Ovarian Stimulation in ART. Principles and Practice of Controlled Ovarian Stimulation in ART
171
196
.
Rogério de Barros Ferreira Leão & Sandro C. Esteves. 2015. Unexplained Infertility. Unexplained Infertility
293
322
.
Rogério de Barros F. Leão & Sandro C. Esteves. (2014) Gonadotropin therapy in assisted reproduction: an evolutionary perspective from biologics to biotech. Clinics 69:4, pages 279-293.
Crossref
Crossref
Diego Ezcurra & Peter Humaidan. (2014) A review of luteinising hormone and human chorionic gonadotropin when used in assisted reproductive technology. Reproductive Biology and Endocrinology 12:1, pages 95.
Crossref
Crossref
Michael H. Dahan, Mohammed Agdi, Fady Shehata, WeonYoung Son & Seang Lin Tan. (2014) A comparison of outcomes from in vitro fertilization cycles stimulated with either recombinant luteinizing hormone (LH) or human chorionic gonadotropin acting as an LH analogue delivered as human menopausal gonadotropins, in subjects with good or poor ovarian reserve: A retrospective analysis. European Journal of Obstetrics & Gynecology and Reproductive Biology 172, pages 70-73.
Crossref
Crossref
Joao Batista A Oliveira, Ricardo LR Baruffi, Claudia G Petersen, Ana L Mauri, Adriana M Nascimento, Laura Vagnini, Juliana Ricci, Mario Cavagna & Jose G FrancoJrJr. (2012) A new ovarian response prediction index (ORPI): implications for individualised controlled ovarian stimulation. Reproductive Biology and Endocrinology 10:1.
Crossref
Crossref